Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Treasury Shares (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Treasury Shares data on record, last reported at $144257.0 in Q1 2026.

  • On a quarterly basis, Treasury Shares rose 931.36% to $144257.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $144257.0, a 931.36% increase, with the full-year FY2025 number at $411833.0, down 57.83% from a year prior.
  • Treasury Shares reached $144257.0 in Q1 2026 per RAPP's latest filing, down from $411833.0 in the prior quarter.
  • Over the last five years, Treasury Shares for RAPP hit a ceiling of $1.6 million in Q4 2023 and a floor of -$46702.0 in Q3 2023.
  • A 4-year average of $670592.5 and a median of $607337.5 in 2025 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: soared 2487.59% in 2024, then plummeted 57.83% in 2025.
  • Tracing RAPP's Treasury Shares over 4 years: stood at $1.6 million in 2023, then crashed by 38.42% to $976596.0 in 2024, then tumbled by 57.83% to $411833.0 in 2025, then plummeted by 64.97% to $144257.0 in 2026.
  • Business Quant data shows Treasury Shares for RAPP at $144257.0 in Q1 2026, $411833.0 in Q4 2025, and $544235.0 in Q3 2025.